Peter J Whitehouse

List of Publications by Year
in descending order

60 papers	7,008 citations	147726 31 h-index	155592 55 g-index
60 all docs	60 docs citations	60 times ranked	4454 citing authors

#	Article	IF	Citations
1	Ethical issues in early diagnosis and prevention of Alzheimer disease. Dialogues in Clinical Neuroscience, 2019, 21, 101-108.	1.8	20
2	A randomized controlled trial of disclosing genetic risk information for Alzheimer disease via telephone. Genetics in Medicine, 2018, 20, 132-141.	1.1	36
3	Ekosustav bioetike. Jahr, 2017, 8, 227-243.	0.3	4
4	Disclosing Pleiotropic Effects During Genetic Risk Assessment for Alzheimer Disease. Annals of Internal Medicine, 2016, 164, 155.	2.0	34
5	A Tale of Two Reports: What Recent Publications from the Alzheimerâ€™s Association and Institute of Medicine say about the State of the Field. Journal of Alzheimer's Disease, 2015, 49, 21-25.	1.2	8
6	A randomized noninferiority trial of condensed protocols for genetic risk disclosure of Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 1222-1230.	0.4	28
7	Public Justice. International Journal of Aging and Human Development, 2014, 80, 95-98.	1.0	1
8	InterWell: an integrated school-based primary care model. London Journal of Primary Care, 2013, 5, 106-110.	0.9	8
9	InterWell: an integrated school-based primary care model. London Journal of Primary Care, 2013, 5, 83-7.	0.9	3
10	Describing the Dying Days of â€œAlzheimer's Diseaseâ€: Journal of Alzheimer's Disease, 2011, 24, 11-13.	1.2	15
11	The Future of Dementia: A Case of Hardening of the Categories. American Journal of Geriatric Psychiatry, 2010, 18, 755-758.	0.6	0
12	Changing perspectives regarding late-life dementia. Nature Reviews Neurology, 2009, 5, 649-658.	4.9	259
13	Disclosure ofAPOEGenotype for Risk of Alzheimer's Disease. New England Journal of Medicine, 2009, 361, 245-254.	13.9	490
14	National Institute of Health and Clinical Excellence Decision Processes Supported by UK High Court: The Debate about the Value of Alzheimer's Disease Drugs Continues. Journal of Alzheimer's Disease, 2008, 13, 239-240.	1.2	0
15	Involuntary emotional expressive disorder: A case for a deeper neuroethics. Neurotherapeutics, 2007, 4, 560-567.	2.1	3
16	Quality of life: The bridge from the cholinergic basal forebrain to cognitive science and bioethics. Journal of Alzheimer's Disease, 2006, 9, 447-453.	1.2	11
17	The End of AD Part 3. Alzheimer Disease and Associated Disorders, 2006, 20, 195-198.	0.6	3
18	Antiaging Medicine and Mild Cognitive Impairment: Practice and Policy Issues for Geriatrics. Journal of the American Geriatrics Society, 2005, 53, 1417-1422.	1.3	31

#	Article	IF	Citations
19	Anthropological contributions to the understanding of age-related cognitive impairment. Lancet Neurology, The, 2005, 4, 320-326.	4.9	33
20	Who seeks genetic susceptibility testing for Alzheimerâ€™s disease? Findings from a multisite, randomized clinical trial. Genetics in Medicine, 2004, 6, 197-203.	1.1	101
21	Paying attention to acetylcholine: the key to wisdom and quality of life?. Progress in Brain Research, 2004, 145, 311-317.	0.9	12
22	Regulatory aspects of mild cognitive impairment: toward a harmonized perspective. Dialogues in Clinical Neuroscience, 2004, 6, 409-414.	1.8	2
23	Reasons for Seeking Genetic Susceptibility Testing Among First-Degree Relatives of People With Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2003, 17, 86-93.	0.6	82
24	Van Rensselaer Potter: An Intellectual Memoir. Cambridge Quarterly of Healthcare Ethics, 2002, 11, 331-334.	0.5	9
25	Managed Care and Complementary and Alternative Medicine: Lessons from the Past and Suggestions for the Future. Journal of Alternative and Complementary Medicine, 1999, 5, 1-2.	2.1	1
26	Progress in the Management of Alzheimer's Disease. Hospital Practice (1995), 1998, 33, 151-166.	0.5	5
27	Evaluation of Dementia. New England Journal of Medicine, 1996, 335, 330-336.	13.9	185
28	Fairhill Guidelines on Ethics of the Care of People With Alzheimer's Disease: A Clinical Summary*. Journal of the American Geriatrics Society, 1995, 43, 1423-1429.	1.3	108
29	Alteration of Phospholipase Câ€Î´ Protein Level and Specific Activity in Alzheimer's Disease. Journal of Neurochemistry, 1995, 64, 2629-2634.	2.1	25
30	Pharmacotherapy for Alzheimerâ€™s Disease. Clinics in Geriatric Medicine, 1994, 10, 339-350.	1.0	7
31	Aberrant Phosphoinositide Metabolism in Alzheimer's Diseasea. Annals of the New York Academy of Sciences, 1993, 695, 46-49.	1.8	8
32	A Double-Blind, Placebo-Controlled Multicenter Study of Tacrine for Alzheimer's Disease. New England Journal of Medicine, 1992, 327, 1253-1259.	13.9	627
33	Alzheimer's Disease: Relationship of Cognition and Behavior to Neurochemistry. International Psychogeriatrics, 1992, 4, 71-78.	0.6	9
34	Dementia: Nosology and Brain-Behavior Relationships. Dementia and Geriatric Cognitive Disorders, 1991, 2, 116-120.	0.7	0
35	Assessment of Behavioral and Affective Symptoms in Alzheimer's Disease. Journal of Geriatric Psychiatry and Neurology, 1990, 3, 21-30.	1.2	145
36	Parkinson's disease and Alzheimer's disease: New neurochemical parallels. Movement Disorders, 1989, 4, S57-S62.	2.2	10

#	Article	IF	Citations
37	Bilateral changes in neocortical [3H]pirenzepine and [3H]oxotremorine-M binding following unilateral lesions of the rat nucleus basalis magnocellularis: an autoradiographic study. Brain Research, 1989, 483, 367-372.	1.1	33
38	Alzheimer's Dementia: Performance on parallel forms of the Dementia Assessment Battery. Neuropsychology, Development and Cognition Section A: Journal of Clinical and Experimental Neuropsychology, 1989, 11, 899-912.	1.4	26
39	Abnormalities in Corticotropin-releasing Hormone (CRH) in Alzheimer's Disease and Other Human Disorders. Annals of the New York Academy of Sciences, 1987, 512, 237-247.	1.8	45
40	Muscarinic and nicotinic cholinergic binding sites in alzheimer's disease cerebral cortex. Brain Research, 1987, 436, 62-68.	1.1	145
41	Corticotropin-releasing hormone (CRH) is decreased in the basal ganglia in Huntington's disease. Brain Research, 1987, 437, 355-359.	1.1	33
42	Immunohistochemical study of neurons containing corticotropin-releasing factor in Alzheimer's disease. Synapse, 1987, 1, 405-410.	0.6	66
43	Loss of pedunculopontine neurons in progressive supranuclear palsy. Annals of Neurology, 1987, 22, 18-25.	2.8	181
44	Aminergic systems in Alzheimer's disease and Parkinson's disease. Annals of Neurology, 1987, 22, 229-236.	2.8	230
45	Dysfunction and Death of Neurons in Human Degenerative Neurological Diseases and in Animal Models. Novartis Foundation Symposium, 1987, 126, 30-48.	1.2	9
46	Cellular pathology in Alzheimer's and Parkinson's diseases. Trends in Neurosciences, 1986, 9, 29-33.	4.2	67
47	Cholinergic receptors in aging and Alzheimer's disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1986, 10, 665-676.	2.5	68
48	Nicotinic acetylcholine binding sites in Alzheimer's disease. Brain Research, 1986, 371, 146-151.	1.1	541
49	Primary Degenerative Dementia Without Alzheimer Pathology. Canadian Journal of Neurological Sciences, 1986, 13, 462-470.	0.3	69
50	The concept of subcortical and cortical dementia: Another look. Annals of Neurology, 1986, 19, 1-6.	2.8	195
51	Reciprocal changes in corticotropin-releasing factor (CRF)-like immunoreactivity and CRF receptors in cerebral cortex of Alzheimer's disease. Nature, 1986, 319, 593-595.	13.7	260
52	Molecular Approaches to Human Neurological Diseases and Their Animal Models. , 1986, , 171-180.		1
53	Neuropathological processes in Alzheimer's disease. Drug Development Research, 1985, 5, 59-68.	1.4	6
54	Neurotransmitter receptors in amyotrophic lateral sclerosis: Possible relationship to sparing of eye movements. Annals of Neurology, 1985, 17, 518-518.	2.8	9

#	Article	IF	Citations
55	Neurotransmitter receptor alterations in Huntington's disease: Autoradiographic and homogenate studies with special reference to benzodiazepine receptor complexes. Annals of Neurology, 1985, 18, 202-210.	2.8	83
56	Abnormalities of the nucleus basalis in Down's syndrome. Annals of Neurology, 1985, 18, 310-313.	2.8	196
57	Corticotropin-Releasing Factor Receptors in Human Pituitary Gland: Autoradiographic Localization. Neuroendocrinology, 1985, 40, 419-422.	1.2	50
58	Basal forebrain neurons in the dementia of Parkinson disease. Annals of Neurology, 1983, 13, 243-248.	2.8	527
59	Amyotrophic lateral sclerosis: Alterations in neurotransmitter receptors. Annals of Neurology, 1983, 14, 8-16.	2.8	151
60	Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis. Annals of Neurology, 1981, 10, 122-126.	2.8	1,694